MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, provided an update today on the status of its myoblast program. The program has successfully and safely completed Phase I human clinical trials in more than forty patients in over four independent studies. The Company is in the process of evaluating the data and is working with its scientists to evaluate the size and score of a potential Phase II trial. ACT began its myoblast program for the treatment of heart failure, advanced heart disease, myocardial infarction, and ischemia with the acquisition of Mytogen Inc in 2007.
